A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets
Chun Ting Huang
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorYu Hung Tseng
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorChe Tong Lin
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorChen Yao Su
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorChun Ting Huang
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorYu Hung Tseng
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorChe Tong Lin
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorChen Yao Su
From the Human Protein Process Sciences (HPPS), Research Department, Lille, France; the College of Oral Medicine, Taipei Medical University; the Institute of Oral Biology, National Yang-Ming University; the Department of Microbiology & Immunology, Taipei Medical University; the Gwo-Wei Dental Implant Center; and the Department of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Search for more papers by this authorAbstract
BACKGROUND: Human platelet concentrates (PCs) may be a source material to produce purified growth factors (GFs) for clinical use or cell therapy. However, no fractionation process of therapeutic-grade GF from PCs has ever been developed.
STUDY DESIGN AND METHODS: PCs were virally inactivated by solvent/detergent (S/D) treatment, subjected to oil extraction to remove part of the S/D agents, and fractionated on a SP-Sepharose (SP) chromatographic column equilibrated in a phosphate-buffered saline (PBS) buffer, pH 7.5. The breakthrough was recovered, and the column was washed with the PBS buffer and then eluted by a 0.7 mol/L NaCl-PBS buffer pH 7.5 (SP-eluate). The SP-breakthrough and SP-eluate were characterized for their content in GF, proteins, lipids, and S/D agents. The MTS value of three cell lines cultivated in a medium containing 10% fetal bovine serum supplemented with 1% to 3% of SP-eluate or recombinant human (rHu) platelet-derived growth factor (PDGF)-BB was compared.
RESULTS: The SP-eluate contained a mean of 47, 17, and 6 ng/mL PDGF-AB, -BB, and -AA, respectively, and 0.26 ng/mL vascular endothelial growth factor (VEGF). It was largely depleted of transforming growth factor-β1 (2.33 ng/mL), epidermal growth factor (0.09 ng/mL), insulin-like growth factor (3.40 ng/mL), albumin, immunoglobulin (Ig)G, IgM, IgA, and fibrinogen, which were mostly in the breakthrough. tri-n-butyl phosphate and Triton X-45 were less than 2 ppm. Cell growth–promoting activity of the SP-eluate was at least as good as that of rHu-PDGF-BB.
CONCLUSION: Human PC can be fractionated into a purified, virally inactivated PDGF and VEGF concentrate, opening perspectives for the development of a new range of blood products for clinical use and cell therapy procedures.
REFERENCES
- 1 Maguire PB, Fitzgerald DJ. Platelet proteomics. J Thromb Haemost 2003; 1: 1593-601.
- 2 Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23: 177-89.
- 3 Borzini P, Mazzucco L. Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point? ISBT Sci Ser 2007; 2: 272-81.
- 4 Borzini P, Mazzucco L. Platelet gels and releasates. Curr Opin Hematol 2005; 12: 473-9.
- 5 Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55: 1294-9.
- 6 Oyama T, Nishimoto S, Tsugawa T, Shimizu F. Efficacy of platelet-rich plasma in alveolar bone grafting. J Oral Maxillofac Surg 2004; 62: 555-8.
- 7 Green DM, Klink B. Platelet gel as an intraoperatively procured platelet-based alternative to fibrin glue. Plast Reconstr Surg 1998; 101: 1161-2.
- 8 Velich N, Nemeth Z, Hrabak K, Suba Z, Szabó G. Repair of bony defect with combination biomaterials. J Craniofac Surg 2004; 15: 11-5.
- 9 Mazzucco L, Medici D, Serra M, Panizza R, Rivara G, Orecchia S, Libener R, Cattana E, Levis A, Betta PG, Borzini P. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. Transfusion 2004; 44: 1013-8.
- 10 Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg 2002; 18: 27-33.
- 11 Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4-15.
- 12 Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A, Micò C, Rambaldi A, Golay J, Introna M. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007; 40: 785-91.
- 13 Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228-36.
- 14 Drengk A, Zapf A, Stürmer EK, Stürmer KM, Frosch KH. Influence of platelet-rich plasma on chondrogenic differentiation and proliferation of chondrocytes and mesenchymal stem cells. Cells Tissues Organs 2009; 189: 317-26.
- 15 Kazemnejad S, Allameh A, Gharehbaghian A, Soleimani M, Amirizadeh N, Jazayeri M. Efficient replacing of fetal bovine serum with human platelet releasate during propagation and differentiation of human bone-marrow-derived mesenchymal stem cells to functional hepatocyte-like cells. Vox Sang 2008; 95: 149-58.
- 16 Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007; 25: 1270-8.
- 17 Salvade A, Della Mina P, Gaddi D, Gatto F, Villa A, Bigoni M, Perseghin P, Serafini M, Zatti G, Biondi A, Biagi E. Characterization of platelet lysate (PL)-cultured mesenchymal stromal cells (MSC) and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods 2009;May 26. [Epub ahead of print.
- 18 Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007; 47: 1436-46.
- 19 Vogel JP, Szalay K, Geiger F, Kramer M, Richter W, Kasten P. Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets 2006; 17: 462-9.
- 20 Zaky SH, Ottonello A, Strada P, Cancedda R, Mastrogiacomo M. Platelet lysate favours in vitro expansion of human bone marrow stromal cells for bone and cartilage engineering. J Tissue Eng Regen Med 2008; 2: 472-81.
- 21 Mirabet V, Solves P, Minana MD, Encabo A, Carbonell-Uberos F, Blanquer A, Roig R. Human platelet lysate enhances the proliferative activity of cultured human fibroblast-like cells from different tissues. Cell Tissue Bank 2008; 9: 1-10.
- 22 Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
- 23 Graves DT, Valentin-Opran A, Delgado R, Valente AJ, Mundy G, Piche J. The potential role of platelet-derived growth factor as an autocrine or paracrine factor for human bone cells. Connect Tissue Res 1989; 23: 209-18.
- 24 Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
- 25 Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
- 26 Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335-46.
- 27 Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006; 117: 143S-9S; discussion 50S-51S.
- 28 Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, Johnston AF, McHugh TP, Anthony MS, Robson LE, Odom LL, Yanagihara D, Pierce GF. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg 1992; 29: 193-201.
- 29 Pierce GF, Tarpley JE, Allman RM, Goode PS, Serdar CM, Morris B, Mustoe TA, Vande Berg J. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 1994; 145: 1399-410.
- 30
Edmonds M,
Bates M,
Doxford M,
Gough A,
Foster A.
New treatments in ulcer healing and wound infection.
Diabetes Metab Res Rev
2000; 16
Suppl
1: S51-4.
10.1002/1520-7560(200009/10)16:1+<::AID-DMRR142>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 31 Perry BH, Sampson AR, Schwab BH, Karim MR, Smiell JM. A meta-analytic approach to an integrated summary of efficacy: a case study of becaplermin gel. Control Clin Trials 2002; 23: 389-408.
- 32 Enestvedt CK, Hosack L, Winn SR, Diggs BS, Uchida B, O'Rourke RW, Jobe BA. VEGF gene therapy augments localized angiogenesis and promotes anastomotic wound healing: a pilot study in a clinically relevant animal model. J Gastrointest Surg 2008; 12: 1762-70; discussion 71-2.
- 33 Ferraro B, Cruz YL, Coppola D, Heller R. Intradermal delivery of plasmid VEGF(165) by electroporation promotes wound healing. Mol Ther 2009; 17: 651-7.
- 34 Anitua E, Sanchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006; 24: 227-34.
- 35 Ball SG, Shuttleworth CA, Kielty CM. Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. J Cell Mol Med 2007; 11: 1012-30.
- 36 Wafai R, Tudor EM, Angus JA, Wright CE. Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J Vasc Res 2009; 46: 45-54.
- 37 Kaya D, Gursoy-Ozdemir Y, Yemisci M, Tuncer N, Aktan S, Dalkara T. VEGF protects brain against focal ischemia without increasing blood-brain permeability when administered intracerebroventricularly. J Cereb Blood Flow Metab 2005; 25: 1111-8.
- 38 Han MK, Kim M, Bae SY, Kang L, Han SY, Lee YS, Rha JH, Kim SU, Roh JK. VEGF protects human cerebral hybrid neurons from in vitro ischemia. Neuroreport 2004; 15: 847-50.
- 39 Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111: 1843-51.
- 40 Ilzecka J. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis? Curr Opin Investig Drugs 2006; 7: 54-9.
- 41 Anghel A, Mut-Vitcu B, Savu L, Marian C, Seclaman E, Iman R, Neghina AM, Dragulescu SI. Clinical improvement after treatment with VEGF(165) in patients with severe chronic lower limb ischaemia. Genomic Med 2007; 1: 47-55.
- 42 Burnouf T, Tseng YH, Kuo YP, Su CY. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. Transfusion 2008; 48: 1090-8.
- 43 Su CY, Kuo YP, Lin YC, Huang CT, Tseng YH, Burnouf T. A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sang 2009; 97: 119-28.
- 44 Shih DT, Liao P, Kuo YP, Burnouf T, Su CY. Functional evaluation of a virally-inactivated human platelet growth factor fraction (Gf-18-f) for the expansion of human mesenchymal stem/stromal cells from adipose tissue. Transfusion 2009; 49: 22A (abstract).
- 45 Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 2006; 46: 2100-8.
- 46 Su CY, Kuo YP, Lin YC, Huang CT, Tseng YH, Burnouf T. A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sang 2009; 97: 119-28.
- 47 Su CY, Kuo JP, Nieh KL, Tseng YH, Burnouf T. Quantitative assessment of the kinetics of growth factors release from platelet gel. Transfusion 2008; 48: 2414-20.
- 48 Burnouf T, Goubran H, Radosevich M, El-Ekiaby M. Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries. ISBT Sci Ser 2007; 2: 121-8.
- 49 Burnouf T, Goubran HA, Radosevich M, El-Ekiaby M. Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems. Transfus Clin Biol 2008; 15: 129-34.
- 50 Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990; 30: 591-8.
- 51 Dichtelmuller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, Von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Pifat D, Osheroff W, Poelsler G. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009; 49: 1931-43.
- 52 CPMP. Guideline on plasma-derived medicinal products (draft). CPMP/BWP/269/95 rev.4. London: The European Agency for the Evaluation of Medicinal Products; 2009. [cited 2010 Mar 29]. Available from: http://www.ema.europa.eu/pdfs/human/bwp/026995endraft.pdf
- 53 Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 24-37.
- 54 Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21: 101-17.